Please login to the form below

human growth hormone

This page shows the latest human growth hormone news and features for those working in and with pharma, biotech and healthcare.

NICE gives Lilly’s Verzenios chance to compete with rivals

Verzenios (abemaciclib) has been recommended in draft guidance by NICE in combination with an aromatase inhibitor for hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)‑negative, locally advanced or ... This is for another

Latest news

FDA takes aim at pharma’s biosimilar-delaying tactics

Insulin action. Gottlieb is also planning to take action on high prices for insulin and other drugs such as human growth hormone which have seen their prices escalate in recent years.
CHMP recommends Teva's generic version of Astellas' Advagraf

The committee also recommended that Faslodex could be used in combination with Pfizer’s breast cancer drug Ibrance (palbociclib) to treat hormone receptor positive, human epidermal growth factor receptor 2-negative ... The combination can also be used
Lilly gets early US approval for Ibrance rival abemaciclib

The US FDA has approved the CDK 4/6 inhibitor - which will be sold as Verzenio - as a combination treatment with hormone drug fulvestrant for hormone receptor-positive, human epidermal growth
Versartis crashes as VELOCITY trial veers off track

The US biotech's somavaratan proved inferior to Pfzier’s Genotropin. US biotech Versartis saw more than 80% wiped off its share price ahead of the weekend after its growth hormone ... The long-acting human growth hormone (hGH) product had been billed
Surging Trulicity takes sting out of Lilly's arthritis setback

New chief executive David Ricks needs the drug and other growth brands to fire on all cylinders to help Lilly ride through the recent disappointment of a surprise FDA rejection for ... receptor-positive (HR+), human epidermal growth factor receptor

More from news
Approximately 1 fully matching, plus 21 partially matching documents found.

Latest Intelligence

Implementing eHealth innovation

Medications management and eHealth. The reference treatment for patients with GHD is based on recombinant human growth hormone (rhGH) which is identical to the growth hormone produced by the pituitary gland. ... growth hormone deficiency, one in which
Pharma deals during December 2014

costs. Pfizer has also signed up to a drug delivery product this month through its $570m licensing deal with Opko Health for a long acting version of human growth hormone (hGH), ... which is currently in phase III trials for the treatment of growth

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Onyx Health Ltd

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping: Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much: Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website: You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...